Regulation & law · 29/11/2016

Braeburn Pharmaceuticals to Develop Dopamine D3 Receptor Selective Antagonists/Partial Agonists for Opioid Use Disorder and Other Conditions

The National Institute on Drug Abuse, part of the National Institutes of Health, Department of Health and Human Services, is considering granting an exclusive patent license to Braeburn Pharmaceuticals, Inc. to develop and commercialize these treatments.